NEW YORK (GenomeWeb News) – Galapagos’ service division, BioFocus DPI, will make cell-based assays for Dart Neuroscience, which will use them in its drug discovery programs for brain disorders, Galapagos said today.
 
The three-year collaboration is potentially worth €4.1 million ($5.4 million) to Galapagos, the Mechelen, Belgium-based firm said.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

The Economist writes that an increasing number of scientific journals don't do peer review.

In Science this week: genetic overlap among many psychiatric disorders, and more.